Cargando…

IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study

BACKGROUND: Little is currently known of the pathophysiological mechanisms triggering Charcot arthropathy and regulating its recovery although foot trauma has been proposed as a major initiating factor by activation of proinflammatory cytokines leading to increased osteoclastogenic activity and prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Folestad, Agnetha, Ålund, Martin, Asteberg, Susanne, Fowelin, Jesper, Aurell, Ylva, Göthlin, Jan, Cassuto, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539704/
https://www.ncbi.nlm.nih.gov/pubmed/26288655
http://dx.doi.org/10.1186/s13047-015-0096-3
_version_ 1782386147999088640
author Folestad, Agnetha
Ålund, Martin
Asteberg, Susanne
Fowelin, Jesper
Aurell, Ylva
Göthlin, Jan
Cassuto, Jean
author_facet Folestad, Agnetha
Ålund, Martin
Asteberg, Susanne
Fowelin, Jesper
Aurell, Ylva
Göthlin, Jan
Cassuto, Jean
author_sort Folestad, Agnetha
collection PubMed
description BACKGROUND: Little is currently known of the pathophysiological mechanisms triggering Charcot arthropathy and regulating its recovery although foot trauma has been proposed as a major initiating factor by activation of proinflammatory cytokines leading to increased osteoclastogenic activity and progressive bone destruction. Several members of the IL-17 family of proinflammatory cytokines have been shown to play a key role in the pathogenesis of inflammatory conditions affecting bone and joints but none has previously been studied in Charcot foot patients. The aim of this study was to investigate the role of IL-17A, IL-17E and IL-17F in patients presenting with Charcot foot. METHODS: Twenty-six consecutive Charcot patients were monitored during 2 years by repeated foot radiographs, MRI and circulating levels of IL-17A, IL-17E and IL-17F. Analysis of cytokines was done by ultra-sensitive chemiluminescence technique and data were analyzed by one-way repeated measures ANOVA. Neuropathic diabetic patients (n = 20) and healthy subjects (n = 20) served as controls. RESULTS: Plasma IL-17A and IL-17E in weight-bearing Charcot patients at diagnosis were at the level of diabetic controls, whereas IL-17F was significantly lower than diabetic controls. A significant increase in IL-17A and IL-17E reaching a peak 2–4 months after inclusion and start of offloading treatment in Charcot patients was followed by a gradual decrease to the level of diabetic controls at 2 years postinclusion. In contrast, IL-17F increased gradually from inclusion to a level not significantly different from diabetic controls after 2 years. CONCLUSIONS: Charcot patients display a significant elevation of all three IL-17 cytokines during the follow-up period relative values at diagnosis and values in control patients supporting a role in the bone repair and remodeling activity during the recovery phase. The rapid increase of IL-17A and IL-17E shortly after initiating off-loading treatment could suggest this to be a response to immobilization and stabilization of the diseased foot.
format Online
Article
Text
id pubmed-4539704
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45397042015-08-19 IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study Folestad, Agnetha Ålund, Martin Asteberg, Susanne Fowelin, Jesper Aurell, Ylva Göthlin, Jan Cassuto, Jean J Foot Ankle Res Research BACKGROUND: Little is currently known of the pathophysiological mechanisms triggering Charcot arthropathy and regulating its recovery although foot trauma has been proposed as a major initiating factor by activation of proinflammatory cytokines leading to increased osteoclastogenic activity and progressive bone destruction. Several members of the IL-17 family of proinflammatory cytokines have been shown to play a key role in the pathogenesis of inflammatory conditions affecting bone and joints but none has previously been studied in Charcot foot patients. The aim of this study was to investigate the role of IL-17A, IL-17E and IL-17F in patients presenting with Charcot foot. METHODS: Twenty-six consecutive Charcot patients were monitored during 2 years by repeated foot radiographs, MRI and circulating levels of IL-17A, IL-17E and IL-17F. Analysis of cytokines was done by ultra-sensitive chemiluminescence technique and data were analyzed by one-way repeated measures ANOVA. Neuropathic diabetic patients (n = 20) and healthy subjects (n = 20) served as controls. RESULTS: Plasma IL-17A and IL-17E in weight-bearing Charcot patients at diagnosis were at the level of diabetic controls, whereas IL-17F was significantly lower than diabetic controls. A significant increase in IL-17A and IL-17E reaching a peak 2–4 months after inclusion and start of offloading treatment in Charcot patients was followed by a gradual decrease to the level of diabetic controls at 2 years postinclusion. In contrast, IL-17F increased gradually from inclusion to a level not significantly different from diabetic controls after 2 years. CONCLUSIONS: Charcot patients display a significant elevation of all three IL-17 cytokines during the follow-up period relative values at diagnosis and values in control patients supporting a role in the bone repair and remodeling activity during the recovery phase. The rapid increase of IL-17A and IL-17E shortly after initiating off-loading treatment could suggest this to be a response to immobilization and stabilization of the diseased foot. BioMed Central 2015-08-18 /pmc/articles/PMC4539704/ /pubmed/26288655 http://dx.doi.org/10.1186/s13047-015-0096-3 Text en © Folestad et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Folestad, Agnetha
Ålund, Martin
Asteberg, Susanne
Fowelin, Jesper
Aurell, Ylva
Göthlin, Jan
Cassuto, Jean
IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study
title IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study
title_full IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study
title_fullStr IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study
title_full_unstemmed IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study
title_short IL-17 cytokines in bone healing of diabetic Charcot arthropathy patients: a prospective 2 year follow-up study
title_sort il-17 cytokines in bone healing of diabetic charcot arthropathy patients: a prospective 2 year follow-up study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539704/
https://www.ncbi.nlm.nih.gov/pubmed/26288655
http://dx.doi.org/10.1186/s13047-015-0096-3
work_keys_str_mv AT folestadagnetha il17cytokinesinbonehealingofdiabeticcharcotarthropathypatientsaprospective2yearfollowupstudy
AT alundmartin il17cytokinesinbonehealingofdiabeticcharcotarthropathypatientsaprospective2yearfollowupstudy
AT astebergsusanne il17cytokinesinbonehealingofdiabeticcharcotarthropathypatientsaprospective2yearfollowupstudy
AT fowelinjesper il17cytokinesinbonehealingofdiabeticcharcotarthropathypatientsaprospective2yearfollowupstudy
AT aurellylva il17cytokinesinbonehealingofdiabeticcharcotarthropathypatientsaprospective2yearfollowupstudy
AT gothlinjan il17cytokinesinbonehealingofdiabeticcharcotarthropathypatientsaprospective2yearfollowupstudy
AT cassutojean il17cytokinesinbonehealingofdiabeticcharcotarthropathypatientsaprospective2yearfollowupstudy